1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Oct 2024
Admin
News Article

ERS Genomics, Université De Montréal ink CRISPR/Cas9 License Agreement

Overview

ERS Genomics Limited (ERS), the CRISPR licensing company, and Université de Montréal (UdeM), a leading Canadian research institution renowned for scientific innovation and technology transfer, announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM’s Institute for Research in Immunology and Cancer.

Statement from Université De Montréal

Lynda Adam, PhD, director of technology transfer, innovation and partnerships, Université de Montréal, said: “With the acquisition of this license, we have launched platform services that will broaden access to genome-wide CRISPR screening and data to the research community. Furthermore, this licence enables UdeM researchers to carry out project collaborations and partnerships using CRISPR technology under certain conditions.”

Words from the CEO: ERS Genomics

John E. Milad, CEO, ERS Genomics, commented: “Université de Montréal has a reputation for making outstanding contributions to scientific innovation. Providing this license and access to the CVC patent portfolio has enabled the launch of screening platforms which will play a role in uncovering new therapeutic targets and ultimately improve healthcare outcomes. We look forward to seeing the transformative impact of their work on global medical challenges.”

About CRISPR Gene Editing

CRISPR gene editing is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified.
It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defence system.
The development of the technique earned biochemists Emmanuelle Charpentier (one of the founders of ERS Genomics) and Jennifer Doudna the Nobel Prize in Chemistry in 2020.

ERS Genomics & CRISPR/Cas9 Technology

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs.
Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including bacteria, archaea, yeasts, and algae.
ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

Financial Details of the Agreement Are Not Disclosed

ERS Genomics provides access to the foundational CRISPR/Cas9 CVC intellectual property held by Dr. Emmanuelle Charpentier, a license to which is essential for freedom to operate commercially with CRISPR/Cas9 technology.

Université De Montréal

Deeply rooted in Montreal and dedicated to its international mission, Université de Montréal is a leading research university worldwide and among the five best French-language universities.
With its affiliated schools, Polytechnique Montréal and HEC Montréal, UdeM attracts over $650 million in research funding every year, making it one of Canada’s top university research hubs.
UdeM has over 67,000 students, 2,300 professors and researchers, and an active global network of 450,000 alumni.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!